BACKGROUND:Nowadays, successful treatment of cancer is not only measured by 5-years survival rate, but also by the patient’s quality of life (QOL). Delayed in the seeking of cancer treatment resulted in high morbidity and impact on the quality of life.AIM:This study aims to assess the QOL of patients with gynecologic cancer after therapy. The results of this research can be used as a basis for cancer treatment that should be holistic, not only to eradicate the disease, but also improve QOL.METHODS:A total of 47 respondents who went to the Department of Oncology, Haji Adam Malik Hospital Medan from May to October 2015 were asked to fill out the FACT-G questionnaire for the QOL assessment. The patient’s personal and disease data was taken from the medical records. The data were analysed statistically by one-way ANOVA test.RESULTS:The results showed that the physical, social, emotional and functional of cancer patients were not much different based on the variables studied. The QOL was higher in patients with endometrial cancer compared with other types of cancer. The QOL was also higher in patients who had completed treatment (> 6 months) and early-stages cancer. There was no statistical difference between the QOL of patients with gynecologic cancer based on therapeutic modalities, duration of treatment and the stage of disease (p > 0.05).CONCLUSION:This current study found the QOL, physical, and emotional complaints are still encountered.
RESEARCH RESEARCH Background. Glutathione peroxidase (GPx) is one of the antioxidant enzymes that maintain the balance of reactive oxygen species. GPx has a notable role in the progression of cancer, including ovarian cancer. Synthesis of this enzyme may be down-regulated in cases of ovarian cancer. As far as we are aware, this has not been studied in an Indonesian population. Objective. To identify the difference in serum GPx levels between ovarian cancer patients and healthy controls. Methods. This was an observational analytical study with a case-control design. The study was conducted in the Department of Obstetrics and Gynaecology at the Haji Adam Malik Hospital in Medan, Indonesia. Serum GPx levels were measured in 20 ovarian cancer patients and 20 control subjects. Results. The types of ovarian cancer identified by histopathology in this study included serous adenocarcinoma (n=10; 50%) and various non-serous adenocarcinomas (50%). The mean (SD) serum GPx level was significantly lower in the cancer group (295.235 (244.479) mU/mL) than in the control group (743.546 (131.949) mU/mL) (p<0.0008). The median serum GPx level was lower among patients with serous ovarian cancer (209.915 mU/mL) than among those with non-serous ovarian cancer (338.885 mU/mL), although the difference was not statistically significant (p>0.226). Conclusion. Serum GPx levels were found to be significantly lower in patients with ovarian cancer than in healthy controls. Further studies are needed to determine an appropriate cutoff level for serum GPx in ovarian cancer in this population.
The aim of this study is to evaluate response of cervical cancer stage IB – IIA after neoadjuvant chemotherapy based on VEGF expression. The data were collected from 51 patients’ cervical cancer stage IB – IIA parafin blocks who received chemotherapy ifosfamide – cisplatin before radical hysterectomy at General Hospital Adam Malik Medan. VEGF expression was evaluated from cervical biopsy tissue, and response therapy was evaluated based on tumor size clinically. 20 out of 51 samples with clinically complete response, and the rest are partial response. 18 out of 20 samples with clinically complete response have negative or weak VEGF expression, and 31 out of 51 samples patients were partialy response with moderate or strong VEGF expression. 23 cases with tumor size > 4 cm and 23 cases stage IIA expressed VEGF moderately or strong. Cervical cancer with tumor size < 4 cm and cervical cenncer stage IB with less expressed of VEGF have good response with chemotherapy adjuvant ifosfamide – cis platin.Keyword: ifosfamide-cisplatin, cervical cancer, VEGF
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.